Synergy between NAFLD and AFLD and potential biomarkers

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue , 2015, Pages S29-S34

  Lakshman, Raj ^a   Shah, Ruchi ^a   Reyes Gordillo, Karina ^a   Varatharajalu, Ravi ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

3' UNTRANSLATED REGION; ALCOHOLIC FATTY LIVER; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; FIBROGENESIS; HUMAN; LIPOTOXICITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; SHORT SURVEY; STELLATE CELL; UPREGULATION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLISM;

BIOMARKERS; CYTOKINES; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; MICRORNAS; OXIDATIVE STRESS;

EID: 84942826326     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.05.007     Document Type: Short Survey

References (50)

1. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases. American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
2. O'Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology 2010, 51:307-328.
3. Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012, 32:3-13.
4. Lefkowitch J.H. Morphology of alcoholic liver disease. Clin Liver Dis 2005, 9:37-53.
5. Malik S.M., deVera M.E., Fontes P., Shaikh O., Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009, 9(4):782-793.
6. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115(24):5651-5661.
7. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008, 49(4):608-612.
8. Hannivoort R.A., Gerken G., Hotamisligil G.S., Trauner M., Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012, 56:952-964.
9. Lakshman M.R. Some novel insights into the pathogenesis of alcoholic steatosis. Alcohol 2004, 34:45-48.
10. Lin J., Handschin C., Spiegelman B.M. Metabolic control through PGC1 family of transcription coactivators. Metabolism 2005, 1:361-370.
11. McGarry J.D., Foster D.W. In support of the roles of malonyl-CoA and carnitine acyltransferase I in the regulation of hepatic fatty acid oxidation and ketogenesis. J Biol Chem 1979, 254:8163-8168.
12. Cook G.A., Nielsen R.C., Hawkins R.A., Mehlman M.A., Lakshman M.R., Veech R.L. Effect of glucagon on hepatic malonyl coenzyme A concentration and on lipid synthesis. J Biol Chem 1977, 252:4421-4424.
13. Chalasani N., Gorski J.C., Asghar M.S., et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003, 37(3):544-550.
14. Garcia-Ruiz C., Colell A., Morales A., Kaplowitz N., Fernandez-Checa J.C. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Mol Pharmacol 1995, 48(5):825-834.
15. Cao Q., Mak K.M., Lieber C.S. Cytochrome P4502E1 primes macrophages to increase TNF-alpha production in response to lipopolysaccharide. Am J Physiol Gastrointest Liver Physiol 2005, 289(1):G95-G107.
16. Boden G., She P., Mozzoli M., et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes 2005, 54(12):3458-3465.
17. Wheeler M.D., Kono H., Yin M., et al. The role of Kupffer cell oxidant production in early ethanol- induced liver disease. Free Radic Biol Med 2001, 31(12):1544-1549.
18. Thakur V., Pritchard M.T., McMullen M.R., Wang Q., Nagy L.E. Chronic ethanol feeding increases activation of NADPH oxidase by lipopolysaccharide in rat Kupffer cells: role of increased reactive oxygen in LPS-stimulated ERK1/2 activation and TNF-alpha production. J Leukoc Biol 2006, 79(6):1348-1356.
19. Kono H., Rusyn I., Yin M., et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 2000, 106(7):867-872.
20. Magnusson C., Vaux D.L. Signalling by CD95 and TNF receptors: not only life and death. Immunol Cell Biol 1999, 77(1):41-46.
21. Leist M., Gantner F., Bohlinger I., Germann P.G., Tiegs G., Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 1994, 153(4):1778-1788.
22. Peraldi P., Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem 1998, 182(1-2):169-175.
23. Barnes P.J., Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336(15):1066-1071. [PubMed: 9091804].
24. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275(4):2247-2250.
25. Brenner D.A., O'Hara M., Angel P., Chojkier M., Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature 1989, 337(6208):661-663.
26. Kaufman R.J. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999, 13(10):1211-1233.
27. Kaufman R.J. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002, 110(10):1389-1398.
28. Rutkowski D.T., Kaufman R.J. A trip to the ER: coping with stress. Trends Cell Biol 2004, 14(1):20-28.
29. Gentile C.L., Pagliassotti M.J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008, 19(9):567-576.
30. Feng B., Yao P.M., Li Y., et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 2003, 5(9):781-792.
31. Bird G.L., Sheron N., Goka A.K., Alexander G.J., Williams R.S. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990, 112(12):917-920.
32. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343(20):1467-1476.
33. Iimuro Y., Gallucci R.M., Luster M.I., Kono H., Thurman R.G. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997, 26(6):1530-1537.
34. Nanji A.A., Khettry U., Sadrzadeh S.M. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994, 205(3):243-247.
35. Tilg H., Moschen A.R., Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6(10):772-783.
36. Lancaster J.R., Laster S.M., Gooding L.R. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Lett 1989, 248(1-2):169-174.
37. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440(7086):944-948.
38. Fox-Robichaud A., Kubes P. Molecular mechanisms of tumor necrosis factor alpha-stimulated leukocyte recruitment into the murine hepatic circulation. Hepatology 2000, 31(5):1123-1127.
39. Wang Z., Yao H., Lin S., Zhu X., Shen Z., Lu G., et al. Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 2013, 331:1-10.
40. Miyaaki H., Ichikawa T., Kamo Y., Taura N., Honda T., et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014, 34:302-307.
41. Derdak Z., Villegas K.A., Harb R., Wu A.M., Sousa A., Wands J.R. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol 2013, 58(4):785-791.
42. Jin X1, Chen Y.P., Kong M., Zheng L., Yang Y.D., Li Y.M. Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. J Gastroenterol Hepatol 2012, 27(2):331-340.
43. Yin H., Hu M., Zhang R., Shen Z., Flatow L., You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by downregulating SIRT1. J Biol Chem 2012, 287:9817-9826.
44. Lakner A.M., Steuerwald N.M., Walling T.L., Ghosh S., Li T., et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology 2012, 56(1):300-310.
45. Mann J., Chu D.C., Maxwell A., et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010, 138(2):705-714.
46. Roderburg C., Urban G.W., Bettermann K., Vucur M., Zimmermann H., et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011, 53:209-218.
47. Pirola C.J., Fernández Gianotti T., Castaño G.O., Mallardi P., San Martino J., et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015, 64(5):800-812.
48. Banaudha K., Kaliszewski M., Korolnek T., Florea L., Yeung M.L., Jeang K.T., et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 2011, 53(1):53-61.
49. Tang Y., Banan A., Forsyth C.B., et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 2008, 32:355-364.
50. Balasubramanyam M., Aravind S., Gokulakrishnan K., Prabu P., Sathishkumar C., Ranjani H., et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem 2011, 351:197-205.